AZN Deadline: AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm

Core Viewpoint - Rosen Law Firm is reminding purchasers of AstraZeneca PLC securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the AstraZeneca securities class action is from February 23, 2022, to December 17, 2024 [1]. - Investors who purchased AstraZeneca securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 21, 2025 [3]. Group 2: Legal Allegations - The lawsuit alleges that AstraZeneca made materially false and misleading statements and failed to disclose significant issues, including engaging in insurance fraud in China [5]. - As a result of these actions, AstraZeneca faced increased legal exposure in China, leading to the detention of its China President by law enforcement [5]. - The lawsuit claims that the true details, once revealed, could materially harm AstraZeneca's business activities in China, resulting in damages to investors [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing clients [4].